iTeos Therapeutics, Inc., a biotechnology company specializing in the development of innovative cancer treatments, concluded its Annual Meeting of Stockholders on Monday, with a significant majority of shares represented. The company, based in Watertown, Massachusetts, announced the election of two Class I directors and the ratification of its independent registered public accounting firm for the upcoming fiscal year.
At the meeting, shareholders exercised their votes to appoint Jill M. DeSimone and David K. Lee to the company's board. DeSimone received 28,724,939 votes in favor, while Lee garnered 28,569,456, with minimal withholdings and no broker non-votes affecting the outcome.
Additionally, the appointment of Deloitte Bedrijfsrevisoren / Réviseurs d’Entreprises BV/SRL as the company's independent auditor for the fiscal year ending December 31, 2024, was ratified with an overwhelming majority of 31,530,823 votes for, 62,078 against, and 13,339 abstentions.
The participation rate at the meeting was notable, with 87.88% of the outstanding shares entitled to vote present or represented by proxy, validating the quorum for the transaction of business.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.